Alere Buys Epocal for $166M
Alere Inc. (NYSE: ALR), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health information solutions, announced today that it has acquired Epocal, Inc., a provider of best-in-class technologies that support blood gas and electrolyte testing at the point of care.
In 2009, Alere entered into a definitive agreement with Epocal to acquire all of the company's issued and outstanding equity securities, contingent upon the achievement of gross margin and other financial milestones on or prior to October 31, 2014. After working capital and other adjustments made at closing, Alere paid approximately $166 million cash to acquire Epocal, which includes a $15 million payment for the achievement of the first two financial milestones specified in the agreement. Additional payments of up to $75.5 million could be triggered if milestones linked to the delivery of additional product offerings on the Epocal platform are achieved.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.